Evaluation of immune response to hepatitis A vaccination and vaccine safety in juvenile idiopathic arthritis

Journal of the Chinese Medical Association

Volumn 74, Issue 5, 2011, Pages 205-208

  Erguven, Muferet ^a   Kaya, Bulent ^a   Hamzah, Oznur Yilmaz ^a   Tufan, Fatma ^a  

^a GOZTEPE TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Anti hepatitis A IgG; Anti tumor necrosis factor drugs; Hepatitis A vaccination; Juvenile idiopathic arthritis

Indexed keywords

ETANERCEPT; HEPATITIS A VACCINE; IMMUNOGLOBULIN G; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ABSENCE OF SIDE EFFECTS; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNE RESPONSE; JUVENILE RHEUMATOID ARTHRITIS; MALE; OUTPATIENT DEPARTMENT; PEDIATRICS; SCHOOL CHILD;

ADOLESCENT; ANTIBODIES, VIRAL; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; FEMALE; HEPATITIS A VACCINES; HUMANS; IMMUNOGLOBULIN G; MALE; TUMOR NECROSIS FACTOR-ALPHA; VACCINATION;

EID: 79955604112     PISSN: 17264901     EISSN: 17287731     Source Type: Journal    
DOI: 10.1016/j.jcma.2011.03.004     Document Type: Article

References (30)

1. Hepatitis A vaccines. Wkly Epidemiol Rec 2000, 75:38-44.
2. Public health control of hepatitis A: memorandum from a WHO meeting. Bull World Health Organ 1995, 73:15-20.
3. Gäre B.A., Fasth A. The natural history of juvenile chronic arthritis: a population based cohort study. I. Onset and disease process. J Rheumatol 1995, 22:295-307.
4. Fink C.W., the ILAR Task Force for Classification Criteria A proposal for the development of classification criteria for the idiopathic arthritides of childhood. J Rheumatol 1995, 22:1566-1569.
5. Petty R.E., Southwood T.R., Baum J., Bhettay E., Glass D.N., Manners P., et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 1998, 25:1991-1994.
6. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004, 31:2.
7. Ruitenberg E.J., van Amstel J.A., Brosi B.J., Steerenberg P.A. Mechanization of the enzyme-linked immunosorbent assay (ELISA) for large scale screening of sera. J Immunol Methods 1977, 16:351-359.
8. Singh G., Athreya B.H., Fries J.F., Goldsmith D.P. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum 1994, 37:1761-1769.
9. Sac R.U., Bostanci I., Dallar Y., Cihan G., Atli O. Hepatitis A seroprevalence and demographics in Turkish children in Ankara. Pediatr Int 2009, 51:5-8.
10. Aydogdu S., Ozgenc F., Yurtsever S., Akman S.A., Tokat Y., Yagci R.V. Our experience with fulminant hepatic failure in Turkish children: etiology and outcome. J Trop Pediatr 2003, 49:367-370.
11. Ferreira C.T., Vieira S.M., Kieling C.O., Silveira T.R. Hepatitis A acute liver failure: follow-up of paediatric patients in southern Brazil. J Viral Hepat 2008, 15:66-68.
12. Bendre S.V., Bavdekar A.R., Bhave S.A., Pandit A.N., Chitambar S.D., Arankalle V.A. Fulminant hepatic failure: etiology, viral markers and outcome. Indian Pediatr 1999, 36:1107-1112. Comment in: Indian Pediatr 2000;37:454-6.
13. Cianciara J. Hepatitis A shifting epidemiology in Poland and Eastern Europe. Vaccine 2000, 18(Suppl 1):S68-S70.
14. Green M.S., Block C., Slater P.E. Rise in the incidence of viral hepatitis in Israel despite improved socioeconomic conditions. Rev Infect Dis 1989, 11:464-469.
15. Russo R.A., Rosenzweig S.D., Katsicas M.M. Hepatitis A-associated macrophage activation syndrome in children with systemic juvenile idiopathic arthritis: report of 2 cases. J Rheumatol 2008, 35:166-168.
16. McPeake J.R., Hirst W.J., Brind A.M., Williams R. Hepatitis A causing a second episode of virus-associated haemophagocytic lymphohistiocytosis in a patient with Still's disease. J Med Virol 1993, 39:173-175.
17. Hu J., Li C.W., Ma J.J., Yin J., Wang X.M., Huang W.Y., et al. Macrophage activation syndrome in children with rheumatic disorders: a retrospective study on 6 patients. Zhonghua Er Ke Za Zhi 2006, 44:818-823.
18. Minden K., Niewerth M., Borte M., Singendonk W., Haas J.P. Immunization in children and adolescents with rheumatic diseases. Z Rheumatol 2007, 66:111-112. 114-8, 120 [in German].
19. Balcarek K.B., Bagley M.R., Pass R.F., Schiff E.R., Krause D.S. Safety and immunogenicity of an inactivated hepatitis A vaccine in preschool children. J Infect Dis 1995, 171(Suppl 1):S70-S72.
20. Horng Y.C., Chang M.H., Lee C.Y., Safary A., Andre F.E., Chen D.S. Safety and immunogenicity of hepatitis A vaccine in healthy children. Pediatr Infect Dis J 1993, 12:359-362.
21. Avery R.K. Vaccination of the immunosuppressed adult patients with rheumatological disease. Rheumatol Dis Clin North Am 1999, 25:567-584.
22. Davies K., Woo P. Immunization in rheumatic diseases of childhood: an audit of the clinical practice of British Paediatric Rheumatology Group members and a review of the evidence. Rheumatology 2002, 41:937-941.
23. Malleson P.N., Tekano J.L., Scheifele D.W., Weber J.M. Influenza immunization in children with chronic arthritis: a prospective study. J Rheumatol 1993, 20:1769-1773.
24. Kanakoudi-Tsakalidou F., Trachana M., Pratsidou-Gertsi P., Tsitsami E., Kyriazopoulou-Dalaina V. Influenza vaccination in children with chronic rheumatic diseases and long-term immunosuppressive therapy. Clin Exp Rheumatol 2001, 19:589-594.
25. Kapetanovic M.C., Saxne T., Nilsson J.A., Geborek P. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatology 2007, 46:608-611.
26. GlaxoSmithKline Biologicals HAVRIX® (package insert) 2005, GlaxoSmithKline Biologicals, Rixensart, Belgium.
27. Merck & Company, Inc VAQTA® (package insert) 2005, Merck & Company, Inc., Whitehouse Station, NJ.
28. McMahon B.J., Williams J., Bulkow L., Snowball M., Wainwright R., Kennedy M., et al. Immunogenicity of an inactivated hepatitis A vaccine in Alaska native children and native and non-native adults. J Infect Dis 1995, 171:676-679.
29. Black S., Shinefield H., Hansen J., Lewis E., Su L., Coplan P. A post-licensure evaluation of the safety of inactivated hepatitis A vaccine (Vaqta, Merck) in children and adults. Vaccine 2004, 22:766-772.
30. Niu M.T., Salive M., Krueger C., Ellenberg S.S. Two-year review of hepatitis A vaccine safety: data from the Vaccine Adverse Event Reporting System (VAERS). Clin Infect Dis 1998, 26:1475-1476.